Skip Navigation LinksHome > November 2012 - Volume 117 - Issue 5 > A Novel Mechanism for Sevoflurane Preconditioning-induced Ne...
Anesthesiology:
doi: 10.1097/ALN.0b013e31826cb48c
Editorial Views

A Novel Mechanism for Sevoflurane Preconditioning-induced Neuroprotection

Zuo, Zhiyi M.D., Ph.D.

Free Access
Article Outline
Collapse Box

Author Information

Illustration: A. Joh...
Illustration: A. Joh...
Image Tools
“… the Notch signaling pathway may turn out to be a mediator for many other effects of sevoflurane on the brain.”
THE concept “ischemic preconditioning” was introduced in the literature in 1986.1 It describes a phenomenon in which short episodes of ischemia before a prolonged episode of ischemia provide protection against the detrimental effects of the prolonged ischemia. Subsequently, various stimuli, in addition to short episodes of ischemia, have been shown to induce a preconditioning effect.2,3 It is specifically interesting to anesthesiologists that volatile anesthetics also can induce a preconditioning effect in various organs and systems, including the central nervous system.4–7 Isoflurane, sevoflurane, and desflurane, currently used volatile anesthetics, have been shown to precondition the brain against ischemia in animal studies.6–9 Various intracellular signaling molecules have been implicated in the volatile anesthetic preconditioning-induced neuroprotection.6–9 In this issue of ANESTHESIOLOGY, Yang et al.10 show that activation of the canonical Notch signaling pathway may be involved in sevoflurane preconditioning-induced neuroprotection in mouse brain. Because the involvement of the Notch signaling pathway in volatile anesthetic effects on the brain has not been known previously, this study helps identify the pathway as a novel mechanism for sevoflurane preconditioning-induced neuroprotection, as well as other sevoflurane effects on the brain in a broader term.
The Notch signaling system is complex. There are four Notch proteins-receptors (Notch 1 to Notch 4) and multiple Notch ligands in mammalian cells.11 The Notch receptors exist in a heterodimer when they are in the plasma membrane. The ligands often are transmembrane proteins. Two main types of ligands are called δ-like ligand and Jagged, each of which has subtypes. Once the receptors are bound with the ligands presented by a neighboring cell, the receptors are activated. Activated receptors are subjected to two cleavages in series: first by a disintegrin and metalloproteinase and then by γ-secretase. This process ultimately produces the Notch intracellular domain (NICD) that then travels to the nucleus to associate with the DNA-binding protein (RBP-J). This complex regulates the expression of target proteins, such as Hes and Hey, that are transcription factors.11,12 Thus, the Notch signaling pathway is unique because it does not require a separate intracellular signaling molecule to transmit the signaling to the nucleus. In addition, activation of the Notch signaling pathway may require physical interaction between two neighboring cells because Notch ligands often are transmembrane proteins and not secretory proteins or peptides.
The Notch signaling system is a highly conserved pathway existing in many cell types. This pathway has various functions, including causing increased or decreased cell proliferation, death, and differentiation processes.11,13 Recent studies have shown that the Notch signaling pathway participates in angiogenesis by regulating the conversion of cells contacting a tip cell to stalk cells in the formation of vascular network.14–16 Tip cells are at the tip of angiogenic sprouts. The stalk cells neighboring the tip cells proliferate to form the vessel wall. Importantly, dysregulation of the Notch signaling pathway is involved in many human diseases, such as cancer, congenital diseases, and adult-onset diseases. Congenital diseases include Alagille syndrome, tetralogy of Fallot, and familial aortic valve disease.11,17 Adult-onset diseases include multiple sclerosis and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy.11,13,18 Thus, understanding the regulation of the Notch signaling pathway is clinically relevant.
In the study performed by Yang et al.,10 C57BL/6 mice were exposed to sevoflurane (2.5%) for 1 h each day for 5 consecutive days. The mice were subjected to a 60-min middle cerebral arterial occlusion (MCAO) at 24 h after the last sevoflurane exposure. MCAO is a classic focal brain ischemia model. The mice exposed to sevoflurane before MCAO had smaller brain infarct volumes and better neurologic functions than did the mice exposed only to the carrier gas (oxygen) or air when the assessment was performed at 3 days after the MCAO. These results clearly showed sevoflurane preconditioning-induced neuroprotection. The investigators then showed that sevoflurane preconditioning increased NICD proteins and Hes messenger RNA in the ischemic penumbral brain tissues. A γ-secretase inhibitor, N-[N-(3,5-difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl ester, inhibited the sevoflurane preconditioning-induced NICD increase and neuroprotection. Sevoflurane induced a preconditioning effect in the brains of mice that had one intact and one disrupted allele of the RBP-J gene in their neurons (the RBP-J+/– mice). However, sevoflurane exposure did not induce a preconditioning effect in the brains of RBP-J–deficient mice (the RBP-J–/– mice; both alleles of the RBP-J gene in these mice were disrupted). Collectively, these results suggest that activation of the Notch signaling pathway is needed for sevoflurane preconditioning-induced neuroprotection.
The results of Yang et al.10 indicate that sevoflurane can activate the Notch signaling pathway. It is not known yet how sevoflurane activates this pathway. The possible mechanisms include enhancing the binding between the Notch receptors and ligands, increasing the activity of proteases that cleave Notch receptors, and facilitating the binding of NICD to RBP-J. The investigators also have not identified the proteins downstream of NICD for sevoflurane preconditioning-induced neuroprotection. Because the Notch signaling pathway is involved in a broad range of biologic functions,11,13 alteration of this pathway can affect functions of many cells. Thus, one would think that regulating the proteins that are downstream of the Notch signaling pathway to induce neuroprotection may be more specific and potentially safer than activating the whole Notch signaling pathway. This rationale signifies the importance of identifying the effectors for sevoflurane preconditioning-induced neuroprotection.
There is one significant caveat in the study of Yang et al.10 The RBP-J–/– mice had smaller brain infarct volumes, fewer apoptotic cells in the ischemic penumbra, and better neurologic functions than did wild-type mice after the MCAO. These beneficial effects appeared with sevoflurane preconditioning in wild-type and RBP-J+/– mice. However, exposure of the RBP-J–/– mice to sevoflurane worsened the neurologic outcome to the level of wild-type mice without sevoflurane preconditioning after the MCAO. These results may be difficult to understand. The reasons for these findings are not clear from the study. However, the results suggest that the Notch signaling pathway can be harmful after brain ischemia or reperfusion. Thus, the timing may be critical in determining whether activation of the Notch signaling pathway is translated into protective or harmful effects after brain insults. If this reasoning is correct, it is possible that blocking the beneficial effects of sevoflurane preconditioning via the Notch signaling pathway in the RBP-J–/– mice makes the potentially harmful effects of repeated sevoflurane exposure show up in these mice.
Sevoflurane is one of the most commonly used volatile anesthetics. Although sevoflurane preconditioning-induced neuroprotection has been known for a few years,8 Yang et al. now have suggested a novel mechanism for this protection. More studies are needed to confirm this finding and define how this mechanism leads to neuroprotection. In addition, the Notch signaling pathway may turn out to be a mediator for many other effects of sevoflurane on the brain.
Zhiyi Zuo, M.D., Ph.D.,
Department of Anesthesiology, University of Virginia Health System, Charlottesville, Virginia.zz3c@virginia.edu
Back to Top | Article Outline

References

1. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia. A delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74:1124–36

2. Dirnagl U, Simon RP, Hallenbeck JM. Ischemic tolerance and endogenous neuroprotection. Trends Neurosci. 2003;26:248–54

3. Gidday JM. Cerebral preconditioning and ischaemic tolerance. Nat Rev Neurosci. 2006;7:437–48

4. Kersten JR, Schmeling TJ, Pagel PS, Gross GJ, Warltier DC. Isoflurane mimics ischemic preconditioning via activation of K(ATP) channels. Reduction of myocardial infarct size with an acute memory phase. ANESTHESIOLOGY. 1997;87:361–70

5. Lee HT, Ota-Setlik A, Fu Y, Nasr SH, Emala CW. Differential protective effects of volatile anesthetics against renal ischemia-reperfusion injury in vivo. ANESTHESIOLOGY. 2004;101:1313–24

6. Kapinya KJ, Löwl D, Fütterer C, Maurer M, Waschke KF, Isaev NK, Dirnagl U. Tolerance against ischemic neuronal injury can be induced by volatile anesthetics and is inducible NO synthase dependent. Stroke. 2002;33:1889–98

7. Zheng S, Zuo Z. Isoflurane preconditioning induces neuroprotection against ischemia via activation of P38 mitogen-activated protein kinases. Mol Pharmacol. 2004;65:1172–80

8. Kitano H, Kirsch JR, Hurn PD, Murphy SJ. Inhalational anesthetics as neuroprotectants or chemical preconditioning agents in ischemic brain. J Cereb Blood Flow Metab. 2007;27:1108–28

9. Zuo Z. Are volatile anesthetics neuroprotective or neurotoxic? Med Gas Research. 2012;2:10

10. Yang Q, Yan W, Li X, Hou L, Dong H, Wang Q, Dong H, Wang S, Zhang X, Xiong L. Activation of canonical Notch signaling pathway is involved in the ischemic tolerance induced by sevoflurane preconditioning in mice. ANESTHESIOLOGY. 2012;117:996–1005

11. Kopan R, Ilagan MX. The canonical Notch signaling pathway. Unfolding the activation mechanism. Cell. 2009;137:216–33

12. Iso T, Kedes L, Hamamori Y. HES and HERP families. Multiple effectors of the Notch signaling pathway. J Cell Physiol. 2003;194:237–55

13. Andersson ER, Sandberg R, Lendahl U. Notch signaling. Simplicity in design, versatility in function. Development. 2011;138:3593–612

14. Tammela T, Zarkada G, Nurmi H, Jakobsson L, Heinolainen K, Tvorogov D, Zheng W, Franco CA, Murtomäki A, Aranda E, Miura N, Ylä-Herttuala S, Fruttiger M, Mäkinen T, Eichmann A, Pollard JW, Gerhardt H, Alitalo K. VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signalling. Nat Cell Biol. 2011;13:1202–13

15. Larrivée B, Prahst C, Gordon E, del Toro R, Mathivet T, Duarte A, Simons M, Eichmann A. ALK1 signaling inhibits angiogenesis by cooperating with the Notch pathway. Dev Cell. 2012;22:489–500

16. Moya IM, Umans L, Maas E, Pereira PN, Beets K, Francis A, Sents W, Robertson EJ, Mummery CL, Huylebroeck D, Zwijsen A. Stalk cell phenotype depends on integration of Notch and Smad1/5 signaling cascades. Dev Cell. 2012;22:501–14

17. Garg V, Muth AN, Ransom JF, Schluterman MK, Barnes R, King IN, Grossfeld PD, Srivastava D. Mutations in NOTCH1 cause aortic valve disease. Nature. 2005;437:270–4

18. Louvi A, Arboleda-Velasquez JF, Artavanis-Tsakonas S. CADASIL. A critical look at a Notch disease. Dev Neurosci. 2006;28:5–12

© 2012 American Society of Anesthesiologists, Inc.

Publication of an advertisement in Anesthesiology Online does not constitute endorsement by the American Society of Anesthesiologists, Inc. or Lippincott Williams & Wilkins, Inc. of the product or service being advertised.
Login

Article Tools

Images

Share